Literature DB >> 8622069

Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: does it affect the clinical course?

M Guglielmi1, B De Bernardi, A Rizzo, S Federici, C Boglino, F Siracusa, A Leggio, F Cozzi, G Cecchetto, L Musi, T Bardini, A M Fagnani, G C Bartoli, A Pampaloni, D Rogers, M Conte, C Milanaccio, P Bruzzi.   

Abstract

PURPOSE: To determine whether resection of primary tumor has a favorable influence on outcome of infants (age 0 to 11 months) with stage IV-S neuroblastoma. PATIENTS AND METHODS: Between March 1976 and December 1993, 97 infants with previously untreated neuroblastoma diagnosed in 21 Italian institutions were classified as having stage IV-S disease. Seventy percent were younger than 4 months. Adrenal was the primary tumor site in 64 of 85 patients with a recognizable primary tumor. Liver was the organ most often infiltrated by the tumor (82 patients), followed by bone marrow and skin.
RESULTS: The overall survival (OS) rate at 5 years in 80% and event-free survival (EFS) rate 68%. In 24 infants, the effect of resection of primary tumor could not be evaluated because of rapidly fatal disease progression (n = 8), absence of a primary tumor (n = 12), or partial resection (n = 4). Of 73 assessable patients, 26 underwent primary tumor resection at diagnosis: one died of surgical complications, one relapsed locally and died, and two others relapsed (one of these two locally) and survived, for a 5-year OS rate of 92% and EFS rate of 84%. Of the remaining 47 patients who did not undergo primary tumor resection at diagnosis 11 suffered unfavorable events, of whom five died, for an OS rate of 89% and EFS rate of 75% (no significant difference from previous group). Disease recurred at the primary tumor site in only one five who died, and in only one of six survivors of progression or relapse; in these patients, the primary tumor, located in the mediastinum, was successfully resected.
CONCLUSION: Infants who underwent resection of the primary tumor at diagnosis had no better outcome than those in whom the decision was made not to operate.

Entities:  

Mesh:

Year:  1996        PMID: 8622069     DOI: 10.1200/JCO.1996.14.5.1537

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Resection of primary tumor in stage 4S neuroblastoma: a second study by the Italian Neuroblastoma Group.

Authors:  Stefano Avanzini; Isabella Buffoni; Anna Rita Gigliotti; Stefano Parodi; Irene Paraboschi; Alessandro Inserra; Patrizia Dall'Igna; Anna Maria Fagnani; Giuseppe Martucciello; Mario Lima; Umberto Caccioppoli; Alberto Garaventa; Massimo Conte; Claudio Granata; Angela Rita Sementa; Elisa Tirtei; Giovanni Erminio; Bruno De Bernardi
Journal:  Pediatr Surg Int       Date:  2020-10-29       Impact factor: 1.827

2.  A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy.

Authors:  Brian H Kushner; Kim Kramer; Shakeel Modak; Timothy J Akhurst; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2009-12-15       Impact factor: 3.167

3.  Long-term follow-up of the "wait and see" approach to localized perinatal adrenal neuroblastoma.

Authors:  Denis Andrew Cozzi; Ermelinda Mele; Silvia Ceccanti; Fabio Natale; Anna Clerico; Amalia Schiavetti; Carlo Dominici
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

4.  Paradoxes in dermatology.

Authors:  Keshavmurthy A Adya; Arun C Inamadar; Aparna Palit
Journal:  Indian Dermatol Online J       Date:  2013-04

5.  MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma.

Authors:  Sung-Jen Wei; Thinh H Nguyen; In-Hyoung Yang; Dustin G Mook; Monish Ram Makena; Dattesh Verlekar; Ashly Hindle; Gloria M Martinez; Shengping Yang; Hiroyuki Shimada; C Patrick Reynolds; Min H Kang
Journal:  Cell Death Dis       Date:  2020-05-14       Impact factor: 8.469

6.  Treatment of stage 4s neuroblastoma--report of 10 years' experience of the French Society of Paediatric Oncology (SFOP).

Authors:  G Schleiermacher; H Rubie; O Hartmann; C Bergeron; P Chastagner; F Mechinaud; J Michon
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

7.  Stage 4S Bilateral Adrenal Neuroblastoma in a Newborn.

Authors:  Rahul Gupta; Tariq Ahmed Mala; Praveen Mathur; Rozy Paul; Shahid Amin Mala
Journal:  APSP J Case Rep       Date:  2014-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.